The Pennant Group, Inc. (PNTG) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong growth across various segments, including Medicare admissions, hospice ADC, and senior living revenue. The company shows robust cash flow and strategic positioning in the Southeast market. The Q&A section indicates conservative guidance for integration but highlights positive joint venture performance and strategic opportunities. Despite some management ambiguity, the overall sentiment is positive, driven by strong financial performance and optimistic guidance.
Key Financial Performance
Adjusted Earnings Per Share (EPS) Fourth quarter adjusted EPS was $0.34, contributing to a full-year 2025 adjusted EPS of $1.18. This exceeded the midpoint of the updated annual guidance of $1.16. The increase was attributed to strong operational performance and growth.
Revenue Full-year 2025 revenue was $947.7 million, an increase of $252.5 million or 36.3% year-over-year. The growth was driven by acquisitions, including Signature Healthcare at Home and over 50 locations from UnitedHealth and Amedisys, as well as organic growth in same-store operations.
Adjusted EBITDA Full-year 2025 adjusted EBITDA was $72.5 million, an increase of $19.2 million or 36% year-over-year. Adjusted EBITDA prior to NCI was $76.7 million, an improvement of $21.6 million or 39.2%. The growth was attributed to operational improvements and contributions from acquisitions.
Home Health and Hospice Segment Revenue Fourth quarter revenue for this segment was $233.3 million, an increase of $91.3 million or 64.3% year-over-year. The growth was driven by strong organic growth and newly acquired agencies in the Southeast.
Home Health Admissions Fourth quarter admissions surged 81.3%, and Medicare admissions grew 87.5% year-over-year. Same-store Medicare admissions grew 8.2%, and Medicare revenue per episode increased 3.7%. The growth was attributed to clinical excellence and entrepreneurial leadership.
Hospice Average Daily Census (ADC) Fourth quarter ADC grew to 5,060, a 46.9% increase year-over-year. Same-store ADC increased 8.4%, admissions increased 6.6%, and hospice Medicare revenue per day increased 5.9%. The growth was driven by high-quality care and operational improvements.
Senior Living Segment Revenue Full-year 2025 revenue for this segment was $215 million, an increase of $39.2 million or 22.3% year-over-year. Fourth quarter revenue was $56.1 million, an increase of $9.2 million or 19.6%. The growth was driven by improved occupancy and revenue per occupied room.
Senior Living Segment Adjusted EBITDA Fourth quarter adjusted EBITDA for this segment was $6.1 million, an increase of $1.9 million or 46% year-over-year. The growth was attributed to operational improvements and increased occupancy.
Senior Living Occupancy All-store occupancy rose 200 basis points to 80.6%, and same-store occupancy grew 250 basis points to 82.1% year-over-year. Revenue per occupied room increased 5.6%. The growth was driven by operational improvements and favorable market conditions.
Cash Flow from Operations Full-year 2025 cash flow from operations was $48.3 million, with $21 million generated in Q4. The strong cash flow was attributed to robust earnings and effective cash collections.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Acquisition of Signature Healthcare at Home: Completed acquisition in the Pacific Northwest and integrated into the operating model, improving performance.
Acquisition of UnitedHealth and Amedisys locations: Acquired over 50 locations in the Southeast, expanding reach and operational capacity.
Senior Living acquisitions: Acquired operations and real estate assets, including Twin Rivers Senior Living in Idaho and Honey Creek Heights Senior Living in Wisconsin.
Expansion in the Southeast: Acquired over 50 locations from UnitedHealth and Amedisys, enhancing market presence in Tennessee, Georgia, and Alabama.
Growth in Idaho: Strengthened presence in Idaho with acquisitions and operational improvements.
Operational excellence focus: Emphasis on optimizing performance and integrating newly acquired operations.
Leadership development: Added over 100 leaders to CEO training program and elevated 39 leaders to C-level positions.
Clinical quality improvements: Achieved a CMS star rating of 4.2 in home health and a hospice quality composite score of 97.5%.
Senior Living operational improvements: Increased occupancy rates and revenue per occupied room, with significant EBITDA growth.
Selective acquisitions: Focus on disciplined and opportunistic acquisitions, particularly in senior living.
Integration of acquisitions: Transitioning and integrating newly acquired operations to achieve operational efficiencies and clinical outcomes.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Integration of Acquired Operations: The transition and integration of the former Amedisys and UnitedHealth operations acquired in October 2025 are expected to cause initial choppiness in early results. This includes system and branding transitions and operational inefficiencies during the integration process.
Reimbursement Environment: The reimbursement environment continues to present headwinds, particularly in the home health segment, which could impact financial performance.
Operational Challenges in Senior Living: While there is progress in the senior living segment, there is still substantial opportunity to unlock, indicating ongoing challenges in fully optimizing this segment.
Debt from Acquisitions: The company has a net debt to adjusted EBITDA ratio of 1.7x due to recent acquisitions, which, while under the covenant limit, could pose financial risks if not managed effectively.
Selective Growth Strategy: The company plans to be more selective in acquisitions in the first half of 2026, focusing on ensuring recently acquired operations are on firm footing, which may limit growth opportunities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company projects full-year revenue in the range of $1.13 billion to $1.17 billion, representing a 22.4% increase at the midpoint.
Adjusted EBITDA Guidance for 2026: The company expects adjusted EBITDA to range between $88.5 million and $94.1 million, reflecting a 26% increase at the midpoint.
Adjusted Earnings Per Share (EPS) Guidance for 2026: The company anticipates adjusted EPS to be between $1.26 and $1.36, with a midpoint of $1.31.
Integration of Acquired Operations: The company is focused on integrating over 50 newly acquired locations from UnitedHealth and Amedisys, with the transition expected to complete by October 2026. Initial choppiness in results is anticipated, but operational efficiencies and strong clinical outcomes are expected post-integration.
Senior Living Business Growth: The company plans to continue the upward trajectory in its senior living business, with substantial opportunities to unlock in its portfolio. Occupancy, revenue, and adjusted EBITDA have been climbing consistently.
Selective Acquisitions in 2026: The company remains open to selective and opportunistic acquisitions, particularly in senior living, while being more selective in home health and hospice acquisitions during the first half of 2026.
Operational Excellence Focus: The company aims to optimize performance and drive operational excellence across its portfolio, focusing on both top-line growth and bottom-line improvement.
Cash Flow and Debt Management: The company expects robust cash flows in 2026, which will be used to fund growth and pay down debt from prior acquisitions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is the guidance for the AMAD-LHCG integration conservative?
A:Yes, the guidance is conservative due to the transition of operations, name changes, and additional support being provided during the first three quarters of the year.
Q:How do joint ventures (JVs) perform compared to non-JV agencies, and what is the strategy around JVs?
A:JVs perform well, with local leaders collaborating with health system partners to deliver clinical and financial outcomes. The strategy includes working with acute care partners while continuing to acquire independent agencies.
Q:What are the differences between the Amedisys/UNH asset ramp-up and the Signature transition?
A:Both have strong leaders and teams, but the Amedisys/UNH transition involves a larger scale, transition services agreement, and additional support services. Lessons from the Signature transition have been applied to improve efficiency.
Q:Was the Columbia River operation part of the Signature group of assets?
A:No, Columbia River was acquired seven years ago from a bankrupt health system and has grown significantly since then.
Q:What is the expected same-store revenue growth for home health and hospice in 2026?
A:The expected same-store revenue growth is about 7%.
Q:How is the company addressing the impact of the home health rule on EBITDA?
A:The company has implemented initiatives to maintain or expand margins despite rate decreases, leading to expected margin expansion in 2026.
Q:What are the margin opportunities in senior living, and how are corporate expenses expected to grow?
A:Senior living is expected to see a 100 basis point occupancy increase and 6% RevPOR growth. Corporate expenses are modeled at 6.4%-6.5% of revenue for 2026.
Q:What is the strategic opportunity given the competitive dynamics in home health and hospice?
A:The company sees an opportunity to position itself as a premier independent provider, leveraging its local operating model and clinical outcomes to gain market share and negotiate with payers.
Q:What is the potential for market share gain in the Southeast and the M&A pipeline?
A:The Southeast offers significant growth potential due to consolidation and the company's local operating model. While large acquisitions are paused, there is strong interest in the M&A pipeline.
Q:What is the incremental margin improvement in senior living with a 1% occupancy increase?
A:A 1% occupancy increase is expected to add about $1 million in value, with 30% of incremental revenue flowing to the bottom line.
Q:What are the operating cash flow and CapEx expectations for 2026?
A:Operating cash flow is expected to be $45-$55 million, and CapEx is forecasted at $15 million, partly for building improvements.
Q:What is the expected exit run rate for EBITDA by the end of 2026?
A:The target is to reach the current operational level of 15%-16% EBITDA margin, with an optimal level of 18% being a longer-term goal.
Q:What are the competitive dynamics in the hospice segment?
A:The hospice segment is seeing normalization post-pandemic, with growth driven by the aging population and the company's ability to meet local community needs.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the specific exit run rate for EBITDA by the end of 2026, only stating general targets of 15%-16% and an optimal level of 18%.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alabama potential
Conference Instructions
Group Conference
Guerisoli CEO
Health segment
Home Pacific
Idaho Lewiston
Idaho Twin
Lewiston market
Medicare admission
Medicare day
Midwest portfolio
Mountain today
NCI improvement
NCI increase
NCI share
Nashville service
Northwest model
REITs
Southeast
UnitedHealth
acquisition transition
bed
census
commitment
facility
flywheel
improvement portfolio
increase midpoint
integration effort
leader field
line improvement
location
opportunity living
ownership
people
period
ramp
segment increase
store occupancy
wave
PNTG Transcript
The Pennant Group, Inc. (PNTG) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial performance, optimistic guidance, and strategic growth initiatives. Positive factors include a 9.1% EPS increase, improved cash flows, and successful integration of acquisitions. The Q&A reveals confidence in operational efficiencies and growth prospects, despite some macroeconomic pressures. The company's focus on partnerships, expansions, and operational excellence further supports a positive outlook. However, management's lack of clarity on certain long-term macroeconomic impacts tempers the sentiment slightly. Overall, the company's strategic initiatives and financial improvements suggest a likely positive stock price movement.
The Pennant Group, Inc. (PNTG) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary reveals strong growth across various segments, including Medicare admissions, hospice ADC, and senior living revenue. The company shows robust cash flow and strategic positioning in the Southeast market. The Q&A section indicates conservative guidance for integration but highlights positive joint venture performance and strategic opportunities. Despite some management ambiguity, the overall sentiment is positive, driven by strong financial performance and optimistic guidance.
The Pennant Group, Inc. (PNTG) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call indicates strong financial performance and growth across multiple segments. The positive sentiment is bolstered by optimistic guidance, significant revenue and EPS growth, and promising acquisition strategies. The Q&A reveals proactive management addressing challenges and opportunities, with employees and analysts showing optimism. Despite some uncertainties, the overall outlook remains positive, especially with the anticipated contributions from the Amedisys transaction and ongoing operational improvements.
The Pennant Group, Inc. (PNTG) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary indicates strong revenue growth across multiple segments, particularly in Home Health and Hospice. The Q&A section reveals a positive sentiment towards market opportunities and operational strategies, despite some uncertainties regarding regulatory impacts. The company has raised its revenue guidance, which is a positive indicator. The sentiment is further bolstered by strategic investments and anticipated margin improvements, suggesting a likely positive stock price movement over the next two weeks.
PNTG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
